Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the complement system to treat inflammatory and immune-mediated diseases. The company operates within the biotechnology and pharmaceutical research industries, with a primary emphasis on conditions driven by excessive or dysregulated inflammation. Its core scientific approach centers on selectively inhibiting complement factor C5a, a key inflammatory mediator, rather than broadly suppressing the immune system.
The company’s lead product candidate is vilobelimab (IFX-1), a monoclonal antibody targeting C5a, which has been evaluated across multiple inflammatory indications. InflaRx primarily serves specialty and hospital-based care markets, targeting diseases with high unmet medical need such as dermatologic, pulmonary, and systemic inflammatory disorders. Founded in 2007 as a spin-out from academic research in Germany, the company later reorganized as a Dutch public limited company (N.V.) and listed its shares on the Nasdaq, reflecting its transition from early research to late-stage clinical development.
Business Operations
InflaRx’s operations are organized around the research, development, and clinical advancement of complement-targeting antibody therapies. The company does not currently generate product revenue and instead relies on equity financing and collaboration-related funding to support operations. Its development pipeline has historically included vilobelimab (IFX-1) for indications such as hidradenitis suppurativa and severe inflammatory conditions, as well as earlier-stage complement-related assets.
Operationally, InflaRx conducts clinical development activities in both North America and Europe, working with contract research organizations, academic institutions, and clinical trial sites. The company’s principal operating subsidiary is InflaRx Pharmaceuticals GmbH, which manages much of its research and development activity. Manufacturing of clinical trial materials and specialized antibody technologies is outsourced to qualified third-party partners, consistent with a virtual biotech operating model.
Strategic Position & Investments
InflaRx’s strategy is centered on establishing leadership in selective complement inhibition, differentiating itself from therapies that block the entire complement cascade. Its growth initiatives have focused on advancing vilobelimab through late-stage clinical trials and exploring additional complement-driven indications where targeted C5a inhibition may offer safety or efficacy advantages.
The company has made strategic investments in expanding its clinical and translational research capabilities rather than pursuing large-scale acquisitions. InflaRx has also entered into selective regional or development-focused partnerships at various points to support clinical execution. Its technology platform positions the company within the emerging immunology and inflammation therapeutics sector, with potential applicability across rare and severe inflammatory diseases. Data inconclusive based on available public sources regarding any currently active large pharmaceutical joint ventures.
Geographic Footprint
InflaRx is headquartered in Germany, with its corporate seat organized under Dutch law as InflaRx N.V. The company maintains an operational presence in Europe and the United States, reflecting the geographic scope of its clinical trials, regulatory activities, and investor base.
Its clinical programs have involved trial sites across multiple continents, including North America and Europe, providing international exposure despite the company’s relatively small organizational footprint. While InflaRx does not maintain commercial infrastructure, its global development strategy is designed to support future regulatory submissions in major pharmaceutical markets.
Leadership & Governance
InflaRx is led by an executive team with experience in biotechnology development, clinical research, and pharmaceutical strategy. The leadership emphasizes scientific rigor, disciplined capital allocation, and targeted innovation in immunology-driven diseases.
Key executives include:
- Niels Steensgaard – Chief Executive Officer
- Michael K. Thate – Chief Financial Officer
- Prof. Jörg Köhl – Co-Founder and Scientific Advisor
- Jan L. Egberts – Chief Medical Officer
The company is governed by a supervisory board structure consistent with European corporate standards, overseeing management performance and long-term strategic direction.